Sort
38,696 grants matching “als”
Simultaneous dose and dose rate optimization for clinical FLASH proton radiotherapy
$481,116Hao Gao · University Of Kansas Medical Center · R01 · FY2023 · CA
ANTI-INFLAMMATORY THERAPIES NEUROTOXICALLY INDUCED PD
$481,114Mc Lean Hospital (Belmont, Ma) · R01 · FY2000 · NS
Peer Leaders as HIV Risk Reduction Change Agents Among IDUs in Ukraine
$481,058Robert E Booth · University Of Colorado Denver · R01 · FY2011 · DA
Duration of Behavioral Counseling Treatment Needed to Optimize Smoking Abstinence
$481,052Arthur Garvey · Harvard Medical School · R01 · FY2011 · DA
The development and validation of a novel tool for the assessment of bulbar dysfunction in ALS
$481,005Yana Yunusova · Sunnybrook Research Institute · R01 · FY2021 · DC
The development and validation of a novel tool for the assessment of bulbar dysfunction in ALS
$481,005Yana Yunusova · Sunnybrook Research Institute · R01 · FY2022 · DC
ANTI-INFLAMMATORY THERAPIES NEUROTOXICALLY INDUCED PD
$480,916Mc Lean Hospital (Belmont, Ma) · R01 · FY2001 · NS
Literacy Development for Preschoolers with Hearing Loss
$480,852Erin M Ingvalson · University Of Washington · R01 · FY2021 · DC
Tumor Suppressor Protein, p53
$480,747Ettore Appella · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Predicting and preventing drug metabolism by the human gut microbiome
$480,713Peter James Turnbaugh · University Of California, San Francisco · R01 · FY2020 · HL
Investigating a novel vascular pathway that regulates neuronal survival
$480,710Shanthini Sockanathan · Johns Hopkins University · R01 · FY2025 · AG
Structure/Function of Gap Junctions
$480,696Thaddeus Andrew Bargiello · Albert Einstein College Of Medicine · R01 · FY2009 · GM
The autophagy lysosomal pathway: regulation by progranulin and its role in neurodegenerative disease
$480,683Steven M Finkbeiner · Northwestern University · P01 · FY2020 · AG
RFA-TS-23-001: Assessment of ALS Risk Factors from ALS TDI's Ongoing Natural History Study (n = 784)
$480,595Fernando Gameiro Vieira · Als Therapy Development Foundation · R01 · FY2024 · TS
Assessment of ALS Risk Factors from ALS TDI's Ongoing Natural History Study (n = 784)
$480,595Fernando Gameiro Vieira · Als Therapy Development Foundation · R01 · FY2023 · TS
Development & Malleability from Childhood to Adulthood
$480,549Nicholas S Ialongo · Johns Hopkins University · R37 · FY2011 · DA
TR2 nuclear receptor in vitamin A signaling
$480,529Li-Na Wei · University Of Minnesota · R01 · FY2023 · NS
Characterization and Treatment of the Scarred Vocal Fold
$480,529Diane M Bless · University Of Wisconsin-Madison · R01 · FY2010 · DC
TR2 nuclear receptor in vitamin A signaling
$480,529Li-Na Wei · University Of Minnesota · R01 · FY2025 · NS
Genetic Susceptibility To Carcinogens
$480,500Douglas Bell · National Institute Of Environmental Health Sciences · ZIA · FY2019 · ES
RFA-TS-23-001: Assessment of ALS Risk Factors from ALS TDI's Ongoing Natural History Study (n = 784)
$480,494Fernando Gameiro Vieira · Als Therapy Development Foundation · R01 · FY2025 · TS
Innate Determinants of Microbial Immunity
$480,448Alan Sher · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Developing a PET biomarker to predict response in treatment-resistant depression
$480,435Patrick J Mc Grath · Columbia University Health Sciences · RC1 · FY2010 · MH
MODELING OF HOST IMMUNE RESPONSES AND ANTIVIRAL THERAPY AGAINST HEPATITIS C
$480,307Harel Dahari · University Of New Mexico · P20 · FY2011 · RR
Synaptic Protein Networks, Genetic Risk, and Spine Loss in Schizophrenia
$480,233Matthew L Macdonald · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · MH